Low PSA metastatic androgen-independent prostate cancer

Keyphrases

• Adenocarcinoma 25%
• Blastic 25%
• CA 15-3 25%
• Carbohydrate Antigen 125 (CA125) 25%
• Carbohydrate Antigen 19-9 (CA19-9) 25%
• Carcinoembryonic Antigen 25%
• Chemotherapy 25%
• Chromogranin A 25%
• Cisplatin-based Chemotherapy 25%
• Cisplatin-based Therapy 25%
• Clinical Parameters 50%
• Complete Response 25%
• Disease Sensitivity 25%
• Eosin 25%
• Hematoxylin 25%
• Histopathological Features 25%
• Hormone-sensitive Prostate Cancer 100%
• Immunohistochemical Staining 25%
• Immunoreactivity 25%
• Liver 25%
• Low PSA 100%
• Low Serum 25%
• Lung 25%
• Lymph Node 25%
• Lytic Bone Disease 25%
• Metastasis 25%
• Neuroendocrine Differentiation 25%
• Neuroendocrine Tumor 25%
• Neuron-specific Enolase 25%
• Non-small Cell Lung Cancer (NSCLC) 50%
• Objective Response 25%
• Patient Selection 25%
• Pelvic Mass 25%
• Poor Differentiation 50%
• Primary Tumor 25%
• Prostate Cancer 50%
• PSA Level 25%
• Serum Markers 25%
• Serum PSA 25%
• Small Cell 25%
• Spleen 25%
• Therapeutic Approaches 25%
• Visceral Metastases 25%

Medicine and Dentistry

• Adenocarcinoma 16%
• Androgen 100%
• Bone Disease 16%
• CA 15-3 16%
• CA-125 16%
• Carcinoembryonic Antigen 16%
• Chromogranin A 16%
• Cisplatin 33%
• Eosin 16%
• Haematoxylin 16%
• Immunocytochemistry 16%
• Immunoreactivity 16%
• Lung 16%
• Lymph Node 16%
• Metastatic Carcinoma 16%
• Neuroendocrine Differentiation 16%
• Neuroendocrine Tumor 16%
• Neuron Specific Enolase 16%
• Patient Selection 16%
• Pelvis 16%
• Primary Tumor 16%
• Prostate Cancer 100%
• Small-Cell Carcinoma 33%
• Visceral Metastasis 16%

Biochemistry, Genetics and Molecular Biology

• CA 15-3 50%
• CA-125 50%
• Cancer Cell 100%
• Carcinoembryonic Antigen 50%
• Chromogranin A 50%
• Cisplatin 100%
• Enolase 50%
• Eosin 50%
• Immunocytochemistry 50%
• Immunoreactivity 50%